Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
<body><p>STORY: U.S. stocks ended marginally lower on Friday, with the Dow and S&P 500 each shedding less than a tenth of a percent, and the Nasdaq losing about a quarter of a percent.</p><p>AI-related chip stocks suffered steep declines as some investors worry that the massive spending to build AI data centers may take too long to pay off.</p><p>Robert Conzo is CEO and managing director of The Wealth Alliance.</p><p>"The AI ship, although we love the technology, everyone loves the idea, it's like a cruise ship where the captain knows where they're going, the passengers don't know where this is going, passengers get nervous. The captain is the CEOs of these companies, putting billions and billions and billions of dollars of infrastructure into the AI. The market is the passengers saying, 'When are we going to be profitable here? At what point does profitability come to play?' Analysts are saying 2030, could be longer. And when prices go up, up, up, up higher, suddenly you start to question that value."</p><p>A report that OpenAI was considering delaying its public debut until next year also weighed on risk sentiment related to AI stocks.</p><p>:: Apple</p><p>Elsewhere in the market, shares of Apple rallied more than 3% and partly rebounded from a selloff a day earlier. The tech giant on Thursday raised iPad and MacBook prices, blaming soaring memory and storage chip costs.</p><p>:: Archive</p><p>Shares of ON Semiconductor tumbled almost 24% after the company agreed to acquire chip maker Synaptics in an all-stock deal valued at about $7 billion. Shares of Synaptics dipped more than 3.5%.</p><p>:: Moderna</p><p>On the flipside, shares of Moderna surged almost 13% to their highest level since 2024 after the drug developer hosted an investor event and showcased its pipeline.</p></body>
US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in
Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
Yahoo Finance's Jared Blikre takes a closer look at some of Friday's trending tickers and stories, including Moderna (MRNA), Netflix (NFLX), and ON Semiconductor (ON).
Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
June 26 (Reuters) - Futures tied to the tech-heavy Nasdaq led Wall Street losses on Friday, as chip stocks came under renewed pressure after a sharp rally in the previous session, while some megacap
It's not just a "pandemic stock," after all.
The FDA’s Vaccines and Related Biological Products Advisory Committee has unanimously backed Moderna’s mRNA-based flu shot, mFlusiva, for adults 50 and older, after phase 3 data showed it to be about 27% more effective than a standard flu vaccine. This endorsement positions Moderna’s mRNA platform for a potential second major commercial use beyond COVID-19, expanding its role in routine respiratory vaccination for older adults. We’ll now explore how this unanimous FDA panel support for...
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
Shares of the vaccine maker have been on a hot streak, most recently catalyzed by a positive update from the FDA.
The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups.
The company's pending vaccine approvals could help the stock continue its rise.
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
Jefferies noted that FDA decisions aligned with advisory committee recommendations 84% of the time between 2020 and 2025.
Moderna shares rose 3.5% Thursday after an advisory committee voted to recommend the U.S. Food and Drug Administration approve the biotech’s proposed new flu shot for people 50 and older. The FDA had initially declined to consider Moderna’s application for the shot’s approval, but then agreed to review it after Moderna amended it. The advisory committee vote in favor of the vaccine isn’t binding, but the FDA generally follows such recommendations.
Moderna said an advisory committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 and older.
Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, but it also became a problem for the stock when pandemic demand dropped and investors questioned whether Moderna could develop a stable business beyond one historic product ...
Moderna (NASDAQ:MRNA) shares moved higher on Thursday, building on the previous session’s strong gains as investors focused on a key review of the company’s influenza vaccine by a U. S.
The Morning Bull - US Market Morning Update Thursday, Jun, 18 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.1%, as investors weigh stubborn trade price pressures against a steady Federal Reserve. Import prices for May rose 1.9%, with fuel and lubricants jumping 12.5%, which means businesses are facing higher costs on what they buy from overseas. Export prices climbed 1.3%, the sixth straight monthly rise, hinting that US goods sold...
They haven't peaked yet.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
